Mylan N.V. (MYL) Getting Somewhat Favorable News Coverage, Study Shows
News headlines about Mylan N.V. (NASDAQ:MYL) have been trending somewhat positive this week, Accern Sentiment reports. The research group identifies negative and positive media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Mylan N.V. earned a news impact score of 0.13 on Accern’s scale. Accern also gave news stories about the company an impact score of 46.4441812075595 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have effected Accern’s rankings:
- Mylan Down 24% Year to Date: What’s Troubling the Stock? (finance.yahoo.com)
- Mylan Down 24% Year to Date: What's Troubling the Stock? (finance.yahoo.com)
- Generic Drug Makers Face Pricing Issues Unlike Other Pharma Companies (finance.yahoo.com)
- Mylan Expands Women’s Healthcare Portfolio with Launch of Generic Minastrin 24 FE Tablets (4-traders.com)
- Could Mylan’s Biosimilar Portfolio Be a Long-Term Growth Driver? (finance.yahoo.com)
MYL has been the subject of a number of recent research reports. Zacks Investment Research raised Mylan N.V. from a “sell” rating to a “hold” rating in a report on Thursday, May 25th. Wells Fargo & Company reaffirmed a “market perform” rating and issued a $40.00 target price on shares of Mylan N.V. in a report on Wednesday, May 31st. Royal Bank Of Canada reaffirmed a “hold” rating and issued a $41.00 target price on shares of Mylan N.V. in a report on Tuesday, June 13th. ValuEngine cut Mylan N.V. from a “buy” rating to a “hold” rating in a report on Wednesday, June 14th. Finally, Cantor Fitzgerald initiated coverage on Mylan N.V. in a report on Friday, June 16th. They issued a “neutral” rating and a $41.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. Mylan N.V. has an average rating of “Hold” and an average target price of $43.43.
Shares of Mylan N.V. (NASDAQ MYL) traded up 0.19% during midday trading on Friday, hitting $31.30. The company had a trading volume of 5,203,980 shares. The company has a market capitalization of $16.79 billion, a P/E ratio of 25.30 and a beta of 1.31. Mylan N.V. has a 52 week low of $29.39 and a 52 week high of $45.87. The firm’s 50 day moving average is $31.89 and its 200 day moving average is $37.29.
Mylan N.V. (NASDAQ:MYL) last released its quarterly earnings data on Wednesday, August 9th. The company reported $1.10 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company had revenue of $2.96 billion during the quarter, compared to analysts’ expectations of $3 billion. During the same quarter in the prior year, the firm posted $1.16 EPS. The firm’s quarterly revenue was up 15.7% on a year-over-year basis. Equities research analysts anticipate that Mylan N.V. will post $4.52 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Mylan N.V. (MYL) Getting Somewhat Favorable News Coverage, Study Shows” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/09/22/mylan-n-v-myl-getting-somewhat-favorable-news-coverage-study-shows.html.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.